PDCD1 and neoplasm: For instance, EGFRxCD16axPD-L1 is a trispecific NKCE that activates NK cell-induced killing of EGFR+ tumor cells through CD16a while blocking the binding of PD-L1 to the immune checkpoint receptor PD-1 on activated NK cells, thus reducing NK cell exhaustion (81).